For US Healthcare Professionals Only
For US Healthcare Professionals Only
For adults with intermediate- or high-risk MF1
In my practice, there is no hemoglobin level that precludes me from starting my appropriate patients with MF on Jakafi.
Ruben Mesa, MD, FACP, MPN Expert
There are no contraindications for the use of Jakafi, including in patients with anemia1
When I do have a patient with anemia, I first educate them that a decrease in hemoglobin is to be expected, typically within the range of 1.5 and 2 grams per deciliter. This decrease is typically front-loaded; however, it is often transient. I also explain that a decrease in hemoglobin levels may not limit the impact or long-term outcomes of Jakafi.HEAR MORE ABOUT HOW DR MESA MANAGES ANEMIA
The COMFORT-I study gives me the confidence to not only initiate Jakafi at diagnosis for my patients with MF who have anemia at baseline, but also manage through that anemia while on treatment. And we see in the data that the benefits of Jakafi may balance the potential concerns for anemia.
Ruben Mesa, MD, FACP, MPN Expert
*COMFORT-I was a randomized, double-blind, placebo-controlled, phase 3 study with 309 patients with intermediate-2–risk or high-risk MF. The primary endpoint was the proportion of patients achieving a ≥35% reduction in spleen volume from baseline to week 24 as measured by CT or MRI.1,3
†Anemia at baseline was defined as RBC transfusion within the first 12 weeks prior to the initial dose of Jakafi, or baseline Hb <10 g/dL.2
‡One or more units of RBCs.5
§New-onset transfusion dependency: the use of 2 or more units of RBC product(s) during the final 8 weeks before data-cutoff date in a patient who was not transfusion dependent at baseline.2
BAT=best available therapy; CBC=complete blood count; COMFORT=COntrolled MyeloFibrosis study with ORal JAK inhibitor Treatment; CT=computed tomography; Hb=hemoglobin; JUMP=JAK Inhibitor RUxolitinib in Myelofibrosis Patients; MF=myelofibrosis; MPN=myeloproliferative neoplasm; MRI=magnetic resonance imaging; OS=overall survival; RBC=red blood cell; SEM=standard error of the mean; TSS=Total Symptom Score.
References: 1. Jakafi [package insert]. Wilmington, DE: Incyte Corporation. 2. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807. Supplementary appendix available at: https://www.nejm.org/doi/full/10.1056/nejmoa1110557. 3. Data on file. Incyte Corporation. Wilmington, DE. 4. Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015;100(4):479-488. 5. Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013;98(12):1865-1871. Supplementary appendix available at: https://haematologica.org/article/view/6861.
Indications and Usage
Jakafi® (ruxolitinib) is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.
Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.
Indications and Usage
Jakafi® (ruxolitinib) is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.
Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.